|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Aptamera, Inc. and Assay Designs, Inc. are developing the OncoMarker IHC kit, an immunohistochemical assay that identifies tumor cells by detecting the presence of a specific protein on the cell surface. The OncoMarker IHC kit is designed to identify individual cancer cells in mixed populations of malignant and normal cells. Aptamera's novel target, a protein termed nucleolin, is a biomarker present on the surface of virtually all types of cancer cell lines tested to date. BD Biosciences and Molecular Probes have launched a series of new flow cytometry products incorporating Molecular Probes' Alexa Fluor dye technology that provides multi-parameter flow cytometry with 13-color cell analysis and that are designed to be used on BD's FACSArray bioanalyzer, which is scheduled for release Q3 2003. Beckman Coulter Inc. has entered into a reagent development and distribution agreement with Cell Signaling Technologies Inc. to distribute existing CST reagents and newly co-developed cell signaling reagents optimized for use in flow cytometry. In addition, the companies will co-develop multiplex panels of activation-state specific antibodies to explore, define and monitor major regulatory circuits controlling cell growth, differentiation and cell death using flow cytometry. Great Smokies Diagnostic Laboratory has launched the latest version of its Comprehensive Digestive Stool Analysis (CDSA) to diagnose irritable bowel syndrome, inflammatory bowel disease and colorectal cancer. Pel-Freez Clinical Systems, LLC has launched the complete SSP UniTray product line, which includes low and high resolution HLA typing kits, as well as the UniMatch Plus analysis program. Tm Bioscience Corporation and bioMerieux SA have signed a non-exclusive license agreement for the use of bioMerieux's Factor II (prothrombin) and Factor V Leiden gene patents in Tm's recently launched Tag-It Mutation Detection kits for coagulation disorders. The Tag-It coagulation kits are the first in a menu of Tag-It genotyping kits that Tm Bioscience will be launching over the course of 2003.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: April 1, 2003 |
![[Page Banner Image]](images/hmole.gif){kind=small}
